Stocktoria
DYADIC INTERNATIONAL INC DYAI
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2004-11-05
DYADIC INTERNATIONAL INC financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $3.5M | $2.9M | $2.9M | $2.4M | $1.6M | $1.7M | $1.3M | $758,420 |
| R&D expense | $2.2M | $2.0M | $3.3M | $4.5M | $8.4M | $3.9M | $3.1M | $2.1M | $1.8M |
| Operating income | -$7.2M | -$5.9M | -$8.2M | -$10.2M | -$14.7M | -$10.0M | -$9.3M | -$7.6M | -$7.1M |
| Income tax | — | — | — | — | $0 | $31,318 | $10,306 | -$1.0M | -$66,694 |
| Net income | -$7.4M | -$5.8M | -$6.8M | -$9.7M | -$13.1M | -$9.3M | -$8.3M | -$5.7M | -$2.1M |
| EPS (diluted) | $-0.23 | $-0.20 | — | — | — | — | — | — | — |
| Operating cash flow | -$5.7M | -$4.0M | -$6.7M | -$8.1M | -$11.3M | -$6.6M | -$5.8M | -$4.4M | -$1.7M |
| Cash & equivalents | $4.6M | $6.5M | $6.5M | $5.8M | $15.7M | $20.6M | $4.8M | $2.4M | $5.8M |
| Total assets | $9.9M | $9.9M | $8.2M | $13.7M | $21.3M | $30.1M | $37.5M | $43.3M | $50.7M |
| Total liabilities | $8.7M | $7.5M | $2.3M | $2.6M | $2.9M | $1.6M | — | — | — |
| Shareholders' equity | $1.2M | $2.5M | $5.9M | $11.1M | $18.4M | $28.4M | $35.9M | $42.5M | $50.0M |
Growth · year-over-year · Revenue CAGR 19.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -11.6% | +20.6% | -1.1% | +21.9% | +50.1% | -4.7% | +29.8% | +70.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.